Washington (ANTARA News) – Anti-viral drug remdesivir reduces recovery time in coronavirus patients, according to the results of a full trial published late Friday, three weeks after America’s top infectious disease expert said the study showed that the drug had “clear” benefits. .
Complete results from the study, conducted by the US government agency, the National Institute of Allergy and Infectious Diseases (NIAID), were published by leading medical magazine New England Journal of Medicine.
The United States authorized the use of emergency remdesivir in hospitals on May 1, followed by Japan, while Europe considered the same thing.
The study found that remdesivir, which is injected intravenously daily for 10 days, accelerated the recovery of COVID-19 patients who were hospitalized compared to placebo in clinical trials in more than a thousand patients in 10 countries.
On April 29, NIAID director Anthony Fauci, who has become a trusted face of the US government regarding the coronavirus pandemic, said preliminary evidence showed that remdesivir had “a clear, significant and positive impact on reducing recovery time.”
The National Institutes of Health, of which NIAID is part, said Friday in an online statement that researchers found “remdesivir is most beneficial for patients who are hospitalized with severe diseases that require additional oxygen.”
But the trial authors wrote that the drug did not prevent all deaths.
“Given the high mortality rate despite taking remdesivir, it is clear that treatment with anti-viral drugs alone is not enough,” they said.
About 7.1 percent of patients given remdesivir in the trial group died within 14 days – compared with 11.9 percent in the placebo group.
However, the results are just below the threshold for statistical reliability, which means it could be accidental and not drug ability.
ioco / roc / rbu / axn
to request modification Contact us at Here or [email protected]